Efinopegdutide demonstrated a statistically significant greater proportion of participants achieved MASH resolution without worsening of fibrosis versus placebo at 52 weeks
Meaningful improvements were observed in
NEW YORK, Nov. 4, 2026 /CNW/ -- Fly on Wall Street News Commentary - Wall Street's major indexes rallied together on Wednesday. As of 2:31 p.m. ET, the Dow Jones Industrial Average was up 1,552.12 points, or 3.0%,
ENHANCE-3 study represents Merck’s commitment to addressing the burden of COPD exacerbations
OHTUVAYRE® is the first and only novel inhaled mechanism for the maintenance treatment of COPD in more than 20 years to
Presentations include data on daily and investigational once-weekly oral treatments and investigational once-monthly oral HIV pre-exposure prophylaxis
New data include Phase 3 subgroup analyses and patient-reported
Investigation follows the October 22, 2026 disclosure regarding Merck & Co., Inc.; investors who lost money may have claims to recover their lossesInvestors who lost money on Merck & Co., Inc. ("Merck"
Investigation comes after an October 22, 2026 report concerning Merck & Co., Inc.; shareholders who suffered losses may have claims to recover them
Investors who suffered losses on Merck & Co., Inc.
Investigation centers on the October 22, 2026 news about Merck & Co., Inc.; investors with losses may have potential claims to recover them
Merck & Co., Inc. ("Merck" or the "Company")
Sales Growth Reflects Continued Strength in Oncology and Animal Health, Plus Contributions From Other Products in Broader Portfolio, Including WINREVAIR
Financial Highlights
Total Worldwide Sales Were $18.1
Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE:OGN) He joins Entera with two decades of clinical development, regulatory execution, and
KEYNOTE-C93 showed median progression-free survival (PFS) was more than four times longer for these patients treated with KEYTRUDA as monotherapy (38.2 months) compared to platinum doublet chemotherapy (8.4
TroFuse-005 is the first and only global Phase 3 study of a TROP2 ADC to demonstrate improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy in these patients who have received prior
AUSTIN, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - An mRNA-based cancer therapy designed around each patient’s own tumor has delivered positive Phase 3 results. On October 22, Merck and
Intismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001) compared to KEYTRUDA alone for patients with completely resected stage IIB-IV
NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brain cancer remains one of the hardest cancers to treat, and researchers are under pressure to find therapies that do more than slow the disease for a short time. For
First and only PD-1 inhibitor plus antibody-drug conjugate regimen approved in the European Union (EU) for patients with MIBC regardless of cisplatin eligibility
Merck (NYSE:MRK), known as MSD outside of the United
